Francis Nemeth v. Brenntag North America

New York Court of Appeals·Decided April 26, 2022·No. 24·Published

Opinion

State of New York OPINION Court of Appeals This opinion is uncorrected and subject to revision before publication in the New York Reports.

No. 24 Francis Nemeth, &c., Respondent, v.

Brenntag North America, &c., et al., Defendants, Whittaker, Clark & Daniels, Inc., Appellant.

Bryce L. Friedman, for appellant. Seth A. Dymond, for respondent. Chamber of Commerce of the United States of America et al., Colgate-Palmolive Company et al., Richard L. Kradin et al., amici curiae.

GARCIA, J.:

Plaintiff’s spouse used a commercial talcum powder daily for a period of more than ten years during the 1960s and early 1970s. Decades later, she developed mesothelioma

-2- No. 24 and died as a result. Plaintiff brought this action, alleging that use of the cosmetic powder was a proximate cause of decedent’s illness. A jury agreed and awarded damages. Because plaintiff’s proof of causation was insufficient as a matter of law, we now reverse and dismiss the complaint against defendant.

I.

Florence Nemeth was diagnosed with peritoneal mesothelioma1 in 2012 and passed away from the disease in 2016. Plaintiff—decedent’s husband—sued an array of defendants involved in the manufacturing and distribution of certain products alleged to contain asbestos to which decedent was exposed over the course of her lifetime, on the theory that each product proximately caused her illness. Plaintiff alleged that decedent used lawn care products containing asbestos; worked with construction materials containing asbestos during home renovations; and inhaled asbestos fibers when she laundered the clothing her son wore as an elevator repairman. Plaintiff also alleged that defendant-appellant Whittaker supplied defendant Shulton with talc contaminated with asbestos that was then used in a commercial talcum powder, Desert Flower, which decedent applied daily from 1960 until 1971. Plaintiff settled with all other defendants, and the case went to trial against Whittaker only.

1 Plaintiff’s expert explained that mesothelioma is a tumor of the mesothelia cells, and can occur in “areas where there is mesothelia tissue[, . . . m]ost commonly it’s the pleura [the lining of the lungs] [. . . but it] can also occur in the abdomen, when it’s called peritoneal mesothelioma.”

-3- No. 24 At trial, the jury viewed a videotaped deposition of decedent, in which she explained that she used Desert Flower daily during the relevant time frame, applying the product while inside small unventilated bathrooms and later cleaning up the residual powder. This routine lasted approximately seven minutes each day. Plaintiff then called a geologist, Sean Fitzgerald, who testified about a test—referred to as a “glove box test”—in which he agitated a vintage sample of Desert Flower within a small, sealed plexiglass chamber to simulate decedent’s use of the talc and to capture the released asbestos fibers, in an effort to “target[] the actual exposure.” He testified that he strategically placed filters inside the chamber to simulate “breathing zones.” He concluded that the asbestos fibers in the sample of Desert Flower were “significantly releasable” and that 2.7 million fibers were released into the air of the chamber during his test and so, multiplying that number by the amount of time, duration, and frequency of decedent’s exposure, he concluded that she must have been exposed to “thousands to millions of fibers, billions and trillions when you add it up through repeated use.” Fitzgerald compared this to the ambient level, or what “an average person living in an urban area breathes in,” of 60,000 fibers per day.

Dr. Jacqueline Moline, a doctor of internal medicine, also testified for plaintiff. She told the jury that mesothelioma is a “sentinel health event” or “signal tumor,” meaning that “if someone develops that cancer, . . . then it signals that they’ve had exposure to that particular substance.” She testified that in reaching her conclusions she relied on clinical experience treating patients with mesothelioma, peer reviewed literature discussing epidemiological and case studies, and government standards and regulations governing acceptable levels of asbestos. Dr. Moline concluded that, although “not every inhalation

-4- No. 24 of asbestos fibers results in peritoneal mesothelioma,” because “some exposures to asbestos . . . are trivial and don’t increase a person’s risk,” Desert Flower was “a substantial contributing factor” to decedent’s peritoneal mesothelioma. Relying on Fitzgerald’s testimony regarding releasable asbestos fibers, she testified that decedent’s exposure was “at levels at which multiple studies have shown elevated rates of mesothelioma.”

The jury returned a verdict in plaintiff’s favor, awarding $15 million to the estate and $1.5 million to plaintiff for loss of consortium, and apportioned fault equally between Whittaker and Shulton.2 Whittaker moved for judgment notwithstanding the verdict, arguing that it was not supported by legally sufficient evidence as to causation. The trial court denied the motion.

A divided Appellate Division modified the judgment in connection with the damages awarded, concluding that certain offsets relating to settling defendants had been improperly calculated, but otherwise affirmed, holding that there was sufficient evidence, “consistent with the Court of Appeals’ [precedent] . . . to support the jury’s verdict and conclusion that [decedent] was exposed to a sufficient quantity of asbestos to cause the disease” (183 AD3d 211, 215 [1st Dept 2020]). The court determined that “Fitzgerald’s testimony about the amount of asbestos released in a glove box analysis of [Desert Flower], along with the timing, duration and frequency of [decedent’s] use of that product, with his conclusion that the amount of asbestos greatly exceeded by ‘several [orders] of magnitude’

2 In response to a ruling by the trial court, the parties later stipulated to a reduced award, and judgment against Whittaker was ultimately entered in the amount of approximately $2 million to decedent’s estate and $200,000 for loss of consortium.

-5- No. 24 the amount of asbestos fibers in ambient air, presents a sound basis for the jury’s conclusion” (id. at 230).

One Justice dissented, asserting that plaintiff had both “failed to present expert evidence specifying the level of exposure to respirable asbestos that would have been sufficient to cause peritoneal mesothelioma” and that “plaintiff’s evidence falls short of establishing that Mrs. Nemeth ‘was exposed to sufficient levels of the toxin to cause the illness’ ” (id. at 236-237 [Friedman, J., dissenting], quoting Parker v Mobil Oil Corp., 7 NY3d 434, 448 [2006]). The dissent concluded that the glove box study was insufficient to establish decedent’s exposure level because it did not estimate the quantity of asbestos fibers to which the decedent would have been exposed, and that Dr. Moline’s testimony failed to provide more than “vague, conclusory and subjective terms . . . characteriz[ing] both the level of asbestos exposure sufficient to cause peritoneal mesothelioma . . . and the level of asbestos exposure to which [decedent] allegedly was subjected” (id. at 241-242). The Appellate Division granted leave to appeal to this Court.

II.

A court may set aside a jury verdict on the ground that it is not supported by legally sufficient evidence where “there is simply no valid line of reasoning and permissible inferences which could possibly lead rational [jurors] to the conclusion reached by the jury on the basis of the evidence presented at trial” (Cohen v Hallmark Cards, 45 NY2d 493, 499 [1978]; CPLR 4404 [a]). For the reasons that follow, we conclude that plaintiff failed to introduce sufficient evidence to support the jury’s verdict.

Free access — add to your briefcase to read the full text and ask questions with AI

Francis Nemeth v. Brenntag North America, (N.Y. 2022).

Francis Nemeth v. Brenntag North America (Francis Nemeth v. Brenntag North America) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Johnny C. McClain v. Metabolife International, Inc
401 F.3d 1233 (Eleventh Circuit, 2005)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Wright v. Willamette Industries, Inc.
91 F.3d 1105 (Eighth Circuit, 1996)
Parker v. Mobil Oil Corp.
857 N.E.2d 1114 (New York Court of Appeals, 2006)
Szczerbiak v. Pilat
686 N.E.2d 1346 (New York Court of Appeals, 1997)
People v. Miller
694 N.E.2d 61 (New York Court of Appeals, 1998)
Sean R. v. BMW of North America, LLC
48 N.E.3d 937 (New York Court of Appeals, 2016)
Matteson v. . New York Central Railroad
35 N.Y. 487 (New York Court of Appeals, 1866)
Matter of New York City Asbestos Litig.
2017 NY Slip Op 1523 (Appellate Division of the Supreme Court of New York, 2017)
Acosta v. City of New York
938 N.E.2d 997 (New York Court of Appeals, 2010)
Cornell v. 360 West 51st Street Realty, LLC
9 N.E.3d 884 (New York Court of Appeals, 2014)
Cassano v. Hagstrom
159 N.E.2d 348 (New York Court of Appeals, 1959)
Cohen v. Hallmark Cards, Inc.
382 N.E.2d 1145 (New York Court of Appeals, 1978)
Solomon v. City of New York
489 N.E.2d 1294 (New York Court of Appeals, 1985)
Lustenring v. AC&S, Inc.
13 A.D.3d 69 (Appellate Division of the Supreme Court of New York, 2004)
Matter of New York City Asbestos Litig. v. A.O Smith Water Prods. Co.
32 N.Y.3d 1116 (New York Court of Appeals, 2018)